Vertex Pharmaceuticals (VRTX -1.1%) is under modest pressure on below-average volume in apparent response to unconfirmed chatter that Symdeko (tezacaftor/ivacaftor and ivacaftor) has been linked to multiple deaths.
Shares bottomed at $170.54 (-4%) intraday before recovering.
Update: FAERS states 30 deaths (search by product name).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.